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This commentary inaugurates a new
review series in EMBO Molecular Medicine
focused on mitochondrial diseases. This
area of medicine, which actually encom-
passes most disease areas, has long since
come of age and is now positioned for the
next leap toward the development of
effective therapies. The aims of the review
series are to offer a comprehensive over-
view of this exciting area of medicine and
research and to provide timely discussions
for clinicians and investigators on the new
discoveries elucidating how mitochondrial
metabolism contributes to an expanding
group of complex, heterogeneous, and
difficult-to-tackle diseases.
I n 1962, Rolf Luft reported on the firstpatient suffering from a hypermetabolicdisorder due to mitochondrial dysfunc-
tion (Luft et al, 1962). In the 1970s and
1980s, the basic functional components of
human mitochondrial biology were estab-
lished, including mitochondrial DNA
sequence, transcription machinery, and
respiratory chain biochemistry. However,
the field ignited in 1988 with the first
description of mtDNA mutations in human
disease (Holt et al, 1988; Wallace et al,
1988). During the 1990s, mtDNA genetics
was established as an important aspect of
human medicine and the first nuclear gene
defects underlying mitochondrial dysfunc-
tion were found (Bourgeron et al, 1995).
Over 1,200 nuclear genes encode proteins
targeted to mitochondria, and even more
proteins are somehow functionally linked
with the organelle. The fact that > 6% of
the active genome is dedicated to the
maintenance and function of mitochondria
per se emphasizes the crucial role of the
mitochondria: transforming nutrient energy
to ATP and fine-tuning cellular growth and
catabolism in response to the environmental
and physiological demands (Nunnari &
Suomalainen, 2012).
Only two Luft disease patients have been
reported to date, exemplifying a typical
aspect of mitochondrial disease: a constella-
tion of hundreds of individual rare disorders
with various and differing clinical signs. The
patients often manifest with neurological
symptoms, but may also present with
cardiomyopathy, sudden blindness, hearing
loss or psychiatric symptoms—almost any
symptom really—making the disorders espe-
cially difficult to diagnose. Mitochondrial
diseases are the most common causes of
inherited metabolic disease in adults and
children and yet are still relatively poorly
known among medical practitioners. Indeed,
with an overall frequency of ~1:2,000,
almost 400,000 people in Europe suffer from
a classic genetic mitochondrial disease.
National and international patient organiza-
tions, such as International Mitopatients and
United Mitochondrial Disease Foundation,
do invaluable work in raising awareness and
providing information for health practition-
ers, patients, and their families.
During the past decade, the amount of
knowledge on nuclear genetic causes of
disorders with mitochondrial dysfunction
has extensively increased, providing us with
tools to classify diseases based on genetic
background. This has enabled international
natural history studies and treatment trials
for the rare disorders based on genetic
and phenotypic homogeneity. The genetic
knowledge has also uncovered phenotypic
mimicry, for example, between mitochon-
drial disorders and vitamin metabolic
defects as vitamin B1 and B9 transporter
deficiencies (SLC19A3; FolR1), which mani-
fest with mitochondrial disease-like clinical
symptoms (Leigh-syndrome-like, Alpers-
syndrome-like, respectively). These defects
lead to progressive, lethal neurological
disorders of childhood, if untreated, but
early vitamin supplementation can prevent
progression or even the manifestation of
severe symptoms. The knowledge that
folate- and thiamin transporter defects are
partially curable emphasizes first-line genetic
testing and empirical vitamin B supplemen-
tation to infants immediately upon suspicion
of mitochondrial encephalopathy, even
before establishing a molecular diagnosis.
The number of treatable mitochondrial or
mitochondrial-like disorders is slowly grow-
ing, along with the increased availability of
diagnostic tools and knowledge of the patho-
genic mechanisms. Most mitochondrial
diseases, unfortunately, remain without any
cure.
Molecular genetics discoveries have
enabled the generation of valuable disease
models, which have dramatically increased
our understanding of early disease physiol-
ogy and provided completely new vistas on
molecular pathogenesis and possible
avenues of treatment. Specifically, the
accrued knowledge indicates four modes
through which mitochondria contribute to
health and disease: (i) intramitochondrial
catabolic mechanisms of oxidative phospho-
rylation; (ii) mitochondrial signals and
metabolites that affect cytoplasmic organel-
lar functions (autophagy, endoplasmic
reticulum, lysosomes, peroxisomes) and
intermediary metabolism; (iii) mitochondrial
roles in inducing metabolic cytokine
secretion and tuning distant organs; and
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(iv) genetic susceptibility of mitochondria
to external insults. These mechanisms
have high relevance for understanding both
the unique spectrum of tissue-specific
mitochondrial disease manifestations and
mechanisms of cellular maintenance and
degenerative diseases, including neurode-
generation, stem cell biology, and aging.
The series begins with Valeria Tiranti’s
review in this issue on the genetic defects
exposing mitochondria to environmental/
metabolic toxins. Tiranti et al originally
discovered ETHE1 mutations as causative of
an atypical mitochondrial disease clinical
phenotype, involving microangiopathy,
diarrhea, and progressive early-onset
encephalopathy, associated with mitochon-
drial cytochrome c oxidase (COX) defi-
ciency. ETHE1 encodes a persulfide oxidase
that neutralizes hydrogen sulfide, a COX
inhibitor and gasotransmitter. Ethe1 defi-
ciency in patients leads to increased H2S
levels in tissues, as well as in the intestine,
where anaerobic bacteria produce the gas.
Remarkably, diarrhea was relieved by the
antibiotic metronidazole and microangiopa-
thy by N-acetyl-cysteine, a glutathione
precursor (Tiranti et al, 2009). These find-
ings introduced completely new concepts in
mitochondrial medicine, by indicating the
susceptibility of intra-organellar metabolism
to changes in the cytoplasmic and even
extracellular environments. Furthermore,
they indicated that a genetic defect can
sensitize intestinal cell mitochondria to
metabolites produced by gut bacteria, lead-
ing to clinical manifestations. Understand-
ing basic intermediary metabolism and its
links to mitochondrial function and disease
may well reveal similar pathogenic routes
underlying progressive disorders.
Mitochondria are the organelles that
burn nutrients to produce the main energy
currency, ATP. It should therefore come
to no surprise that their dysfunction
impacts nutrient signaling. Recent data
obtained in mitochondrial disease mouse
models have indicated that modifying
NAD+ metabolism for example with vita-
min B3 derivatives may delay progression
of adult-onset mitochondrial myopathy
(Khan et al, 2014), leading to mitochon-
drial biogenesis and activation of sirtuins,
thus linking late-onset mitochondrial
disease pathogenesis directly with abnor-
mal nutrient sensing mechanisms. Further-
more, mitochondrial myopathy induces the
secretion of a metabolic cytokine, FGF21,
from muscle to blood, recruiting lipids
from fat stores (Tyynismaa et al, 2010).
This indicates that a single tissue with
mitochondrial dysfunction can have direct
metabolic consequences in the whole
organism in a cell non-autonomous fash-
ion. In addition to its mechanistic rele-
vance, FGF21 has also become a useful
serum marker for mitochondrial muscle
disease. The mechanistic implications of
these findings are also relevant for condi-
tions with secondary mitochondrial
dysfunction, including aging. I will discuss
the impact of mitochondrial dysfunction in
nutrient signaling and the therapeutic
opportunities offered by this knowledge in
another upcoming review.
Mitochondria are dynamic organelles,
which change their shape and location
depending on cellular cues and needs, in
tight interaction with the cytoskeleton and
cellular events such as calcium currents in
neurons (Kasahara & Scorrano, 2014).
Furthermore, mitochondria interact with
other cellular organelles, which in turn
regulate their dynamics and metabolism.
For example, the endoplasmic reticulum has
direct tight contacts with mitochondria,
marking the sites of organelle division
(Friedman et al, 2011), and mitochondria
can bud small vesicles fusing to peroxi-
somes or lysosomes and carrying cargo
(Soubannier et al, 2012). The potential of
treatment strategies affecting mitochondrial
division machinery, morphology, recycling
and repair are an active field of research,
and will be the topic of Luca Scorrano’s
contribution to this series.
Mitochondrial signals can modify cellular
behavior and differentiation at multiple
levels. Despite the assumption that mito-
chondrial dysfunction and aging are associ-
ated with increased amounts of reactive
oxygen species (ROS), evidence of increased
oxidative damage has not been found in
mouse models with mtDNA mutagenesis
(Trifunovic et al, 2004; Kujoth et al, 2005).
Instead, these models have indicated the
sensitivity of the stem cell compartment to
subtle increases in superoxide radicals,
which commit progenitor cells toward prolif-
eration and differentiation (Ahlqvist et al,
2012; Ha¨ma¨la¨inen et al, 2015). Indeed, mito-
chondrial quiescence is essential for stem
cell quiescence; mitochondrial mutagenesis
in pluripotent tissue stem cells is thus a
threat for maintenance of their stemness.
The importance of ROS signaling for stem
cells makes them also sensitive to mitochon-
drial antioxidants—a completely understudied
field, and an important aspect in assessing
intervention effects for different cell types.
Mike Murphy will discuss the exciting field
of ROS biology in mitochondrial disease in
another upcoming review.
Finally, two reviews by Patrick Chinnery
and Jan Smeitink will present and discuss
the complex, complementary, and yet
diverging clinical and genetic landscapes of
adult and pediatric mitochondrial disease,
respectively.
Nutrients, vitamins, metabolites, and
antioxidants can crucially affect mitochon-
drial homeostasis and cell maintenance.
Understanding the molecular mechanisms of
the cross talk between mitochondria and the
cellular and extracellular environments in
different tissues will be the key to explaining
the variable manifestations of mitochondrial
pathology, assessing treatment options and
their adverse effects. Considerable recent
increase in knowledge of mitochondrial
disease physiology in mice, however, justi-
fies careful optimism concerning treatment
of mitochondrial dysfunction and challenges
scientists to take the essential steps toward
human trials.
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